However, this route of immunization is associated with the occurrence of facial nerve paralysis (Bell’s Palsy) as a result of the use of Escherichia coli heat-labile

toxin (LT) or mutants thereof, as adjuvant. Clearly, the use of toxins or toxoids should be avoided as nasal adjuvant. An example of a Libraries recently developed nasal immunostimulatory system is the bacterium-like particle (BLP) derived from the food-grade bacterium Lactococcus lactis [13] and [14]. BLPs are obtained by an acid pre-treatment, which degrades all cellular components, including DNA and proteins but leaves the peptidoglycan shell intact. The result is a non-living particle that still has the shape and size of an untreated bacterium. The procedure is applicable to all Gram-positives, hence the name that was formerly used: Gram-positive Enhancer Wortmannin ic50 Matrix (GEM) [13] and [14]. Because of their safe use and adjuvant activity [15] and [16], Bosutinib molecular weight BLPs are an attractive adjuvant candidate for the development of nasal influenza vaccines. Previously, we showed that intranasal (i.n.) immunization with influenza monovalent subunit vaccine of strain A/Wisconsin (H3N2) mixed

with BLPs strongly potentiate immunogenicity of influenza subunit vaccine resulting in both local and systemic immune responses [15] and [16]. In vitro studies using a panel of human Toll-like receptors (TLRs) expressed in HEK293 cells suggest that BLPs have the capacity to mediate TLR2 signalling. Also, TLR2-specific blocking antibodies reduced the BLP-induced IL6 production by murine CD11c+ DCs in vitro [17]. However, it is currently unclear Edoxaban if TLR2 activation via BLPs is fully responsible for the enhanced activation of the adaptive immune system in vivo as measured by T-cell and B-cell activation. First of all, TLR2 can form heterodimers with other TLRs, specifically TLR1 and TLR6 [18] and [19]. Especially TLR2/TLR1 heterodimers were shown important in the induction

of a protective mucosal Th17 immune response in vivo, whereas TLR2/TLR6 heterodimers were not [20]. In addition, TLR2 is expressed on the surface of a large number of immune cells including macrophages [21], monocytes and dendritic cells [22], M cells [23], B cells [24] and T cells [25] including regulatory T cells [26] capable of differentially regulating the immune response. Although there is ample evidence that vaccination with BLP adjuvanted vaccines induces protective immunity, it remains to be proven whether TLR2 mediated effects are responsible for the observed activation of the adaptive immune response in vivo. To address the proposed role of TLR2 in vivo in the BLP-dependent activation of the adaptive immune system, we explored local and systemic influenza A virus specific T-cell and B-cell responses in TLR2 knockout (TLR2KO) and wild-type control mice after i.n.